scholarly journals Suppression of Colorectal Cancer Growth Using an Adenovirus Vector Expressing an Antisense K-ras RNA

2001 ◽  
Vol 3 (4) ◽  
pp. 491-499 ◽  
Author(s):  
Masaru Nakano ◽  
Kazunori Aoki ◽  
Nobuyuki Matsumoto ◽  
Shumpei Ohnami ◽  
Kazuteru Hatanaka ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adenovirus Vector ◽  
Cancer Growth

Corrigendum to “Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis” [Cancer Lett. 380 (2016) 87–97]

2020 ◽  
Vol 469 ◽  
pp. 526
Author(s):  
Yun-Xin Lu ◽  
Huai Qiang Ju ◽  
Feng Wang ◽  
Le-Zong Chen ◽  
Qi-Nian Wu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Growth ◽  
Nafamostat Mesilate

Possible endocannabinoid control of colorectal cancer growth

2003 ◽  
Vol 125 (3) ◽  
pp. 677-687 ◽  
Author(s):  
Alessia Ligresti ◽  
Tiziana Bisogno ◽  
Isabel Matias ◽  
Luciano De Petrocellis ◽  
Maria Grazia Cascio ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Growth

Baicalein Binds to TLR4, Inhibits Colorectal Cancer Growth and Metastasis via the TLR4/HIF/VEGF Axis

2021 ◽  
Author(s):  
Minting Chen ◽  
Keying Zhong ◽  
Jincheng Tan ◽  
Mingjing Meng ◽  
Chok Mei Liu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Growth

Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions

2022 ◽  
Author(s):  
Muhammad Tufail ◽  
Changxin Wu
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Predictive Biomarkers ◽  
Cancer Growth ◽  
Pharmaceutical Companies ◽  
Future Directions ◽  
System Complexity ◽  
Deadly Disease ◽  
Trial Failure ◽  
Shed Light

IGF-1Rs enact a significant part in cancer growth and its progress. IGF-1R inhibitors were encouraged in the early trials, but the patients did not benefit due to the unavailability of predictive biomarkers and IGF-1R system complexity. However, the linkage between IGF-1R and cancer was reported three decades ago. This review will shed light on the IGF-1R system, targeting IGF-1R through monoclonal antibodies, reasons behind IGF-1R trial failure and future directions. This study presented that targeting IGF-1R through monoclonal antibodies is still effective in cancer treatment, and there is a need to look for future directions. Cancer patients may benefit from using mAbs that target existing and new cancer targets, evidenced by promising results. It is also essential that the academician, trial experts and pharmaceutical companies play their role in finding a treatment for this deadly disease.

scholarly journals Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth

2018 ◽  
Vol 26 (20) ◽  
pp. 5435-5442 ◽  
Author(s):  
Jiangbo Wang ◽  
Robert A. Mook ◽  
Xiu-rong Ren ◽  
Qingfu Zhang ◽  
Genevieve Jing ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Potent Inhibitor ◽  
Cancer Growth

NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo

APOPTOSIS ◽  
2018 ◽  
Vol 24 (1-2) ◽  
pp. 83-94 ◽  
Author(s):  
Qizhao Ma ◽  
Ling Gu ◽  
Shiping Liao ◽  
Yanjiang Zheng ◽  
Shu Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Growth

scholarly journals MiR-130a-3p suppresses colorectal cancer growth by targeting Wnt Family Member 1 (WNT1)

Bioengineered ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 8407-8418
Author(s):  
Guang-Lin Song ◽  
Ming Xiao ◽  
Xiao-Ya Wan ◽  
Jun Deng ◽  
Jun-Da Ling ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Family Member ◽  
Cancer Growth

scholarly journals TrkC promotes colorectal cancer growth and metastasis

Oncotarget ◽  
2017 ◽  
Vol 8 (25) ◽  
pp. 41319-41333 ◽  
Author(s):  
Min Soo Kim ◽  
Kwang Wook Suh ◽  
Suntaek Hong ◽  
Wook Jin
Keyword(s):  
Colorectal Cancer ◽  
Cancer Growth
Sign in / Sign up

Export Citation Format

Share Document